PCSK9 and familial hypercholesterolemia: Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies and small interfering RNA (siRNA) are major breakthroughs in cardiovascular therapeutics that have demonstrated unparalleled efficacy in alleviating hypercholesterolemia and reducing cardiovascular risk [29,30,31].